the t cell compartment is phenotypically and functionally heterogeneous; subsets of naive and memory cells have different functional properties, and also differ with respect to homeostatic potential and the ability to persist in vivo. Human stem cell memory t (t scM ) cells, which possess superior immune reconstitution and antitumor response capabilities, can be identified by polychromatic flow cytometry on the basis of the simultaneous expression of several naive markers together with the memory marker cD95. We describe here a protocol based on the minimum set of markers required for optimal identification of human and nonhuman primate (nHp) t scM cells with commonly available flow cytometers. By using flow sorters, t scM cells can thereby be isolated efficiently at high yield and purity. With the use of the 5.5-h isolation procedure, depending on the number of cells needed, the sorting procedure can last for 2-15 h. We also indicate multiple strategies for their efficient expansion in vitro at consistent numbers for functional characterization or adoptive transfer experiments.
IntroDuctIon
The T cell compartment is highly heterogeneous, and dozens of phenotypically and functionally distinct subsets can be identified in the peripheral blood by polychromatic flow cytometry 1, 2 . Conventionally, memory cells have been divided into central memory (T CM ) and effector memory (T EM ) subsets according to the expression of C-C chemokine receptor 7 (CCR7) and CD62L (L-selectin); these cells home to secondary lymphoid or peripheral tissues, respectively 3 . More recently, a subset of memory T cells with stem cell-like properties (T SCM ) has been identified 4 . These cells are the least differentiated of all distinct memory populations, expressing multiple naive markers and the memory antigen CD95 (Fig. 1) . Functionally, T SCM cells can generate multiple memory T cell populations, and they possess an enhanced self-renewal capacity 4 . In addition, they are endowed with superior immune reconstitution potential in immunodeficient hosts and mediate superior antitumor immunity in a humanized mouse model 4 . Thus, the translational applications of T SCM cells for the development of new vaccines or adoptive T cell therapies are considerable. In mice, T SCM cells specific to the Y antigen have been identified in the setting of allogeneic bone marrow transplantation 5 . Furthermore, cells with T SCM properties could be induced in vitro by the activation of the Wnt/β-catenin pathway in naive T cells stimulated through the T cell receptor (TCR) 6 . However, mouse T SCM cells specific for viral or tumor antigens have not been described so far, and the identification of a mouse T SCM population with relevance in physiology and pathology remains elusive. The NHP is probably the best animal model for human immunity; as far as T cells are concerned, the immune systems are phenotypically similar, and with a few exceptions the same human antibody reagents can be used to delineate T cell subsets in rhesus macaques 7 . Indeed, a population of naivelike cells expressing CD95 can be identified in rhesus macaques ( Fig. 1) , thus allowing the study of T SCM cells in vivo.
Development of the protocol
Human and NHP T SCM cells are relatively rare, comprising about 2-4% of the total CD4 + or CD8 + T cells in the blood. There is no unique marker to phenotypically identify these cells; the expression of any given marker is shared with naive or memory cells. This presents a challenge for the isolation of these cells at high yield and high purity for further functional analyses. By polychromatic flow cytometry, we originally characterized human T SCM cells as simultaneously expressing multiple naive markers including CD45RA, CCR7, CD62L, CD27, CD28, CD127 (IL-7Rα) and CD11a dim and lacking CD45RO; unlike naive T cells (T N ), they also express the memory antigen CD95 (ref. 4) . However, the simultaneous analysis of all of these nine markers is not critical for the identification of human T SCM cells (Fig. 2) ; seven-or eight-color panels ( Table 1) accurately identify and allow for sorting of human and NHP T SCM cells using commonly available flow cytometers. All antibody and fluorochrome combinations described are commercially available.
For human cells (Table 1) , the panels include the following: (i) a 'dump' channel to exclude dead cells with a viability dye; (ii) antibodies to CD3, CD8 and CD4 to define the lineage of interest; (iii) antibodies to CD45RO, CCR7, and either CD62L or a different marker expressed by naive cells (e.g., CD27, CD28 or CD45RA) to identify naive-like cells and subsets of memory cells 8 ; (iv) and anti-CD95 to discriminate CD95 -T N from CD95 + T SCM cells. These panels leave the phycoerythrin (PE) channel open to accommodate an additional antibody of interest, a major histocompatibility complex (MHC) class I tetramer for the identification of antigenspecific CD8 + T cells (Fig. 1d) , or anti-CD58 or anti-CD122 (Fig. 3) . CD58, the lymphocyte function-associated antigen 3, belongs to the immunoglobulin superfamily and mediates the interaction between lymphocytes and CD2, expressed on a variety of cell types including the endothelium. CD122 is the β-chain of the Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells IL-2/IL-15 receptor complex, which forms a low-affinity receptor together with the γ-chain. Both CD58 and CD122 are found at higher levels on conventional memory cells and T SCM cells than on T N cells. This differential expression can be utilized to better identify T SCM cells (Fig. 3a) . In our hands, CD95 is preferred to CD58 and CD122, as CD95-specific antibodies are available through multiple vendors and as conjugates to different fluorochromes, thus allowing the design of complex and interchangeable multicolor panels. Most notably, staining for CD95 provides a better separation of T SCM cells from T N cells by flow cytometry compared with CD58 and CD122. However, the vast majority of CD95 + T SCM cells also coexpress these markers. As an obvious consequence, T SCM cells identified on the basis of the increased expression of CD58 or CD122 also have increased expression of the T SCM core phenotypic marker CD95 (Fig. 3b) , thus indicating that CD58 and CD122 are valid markers for the identification of true T SCM cells. A similar combination of antibodies can be used to identify NHP T SCM cells, e.g., CD45RA, CCR7, CD28, CD95 and CXCR3 ( Table 1 ).
Experimental design
As described, human T SCM cells can be identified as expressing multiple markers of T N cells and also CD95, which is preferentially found on the surface of memory cells. Three markers, i.e., CD45RO, CCR7 and CD62L, are sufficient for the identification of T N -like cells (defined as CD45RO -CCR7 + CD62L + ) and for the exclusion of memory T cell contaminants of unknown function, as can occur when only two markers are used to identify T N cells 8 If a flow cytometer with a limited number of detectors is used (e.g., eight detectors), we suggest using anti-CD45RO instead of anti-CD45RA, as it allows the exclusion of CD45RO + /CD45RA + activated cells. However, if more detectors are available, the additional inclusion of anti-CD45RA helps to better delineates the human T SCM cells. When cryopreserved cells are used, CD62L staining is not reliable because expression is lost with the freezethaw procedure 1 . In this case, we recommend including a different marker for the identification of naive-like cells, such as CD27, CD28 or CD127 (IL-7Rα), as depicted in Figure 1d and Table 1 . Unfortunately, the gating procedure in flow cytometry is highly user dependent. Moreover, given the dim expression of CD95 in T SCM cells compared with conventional memory cells (Fig. 3b) , the separation of T SCM cells from CD95 − T N cells can be difficult. To minimize this problem and to identify T SCM cells consistently, a standardized gating strategy has been developed (Fig. 1a,b) .
We noted that T SCM cells (especially in humans) have slightly lower levels of CCR7 compared with T N cells. This property allows better delineation of T N and T SCM cells when CCR7 is plotted against CD95 expression, and it can be exploited by positioning the sorting gate on a diagonal alongside the T SCM population (Fig. 1a) . Indeed, clear-cut separation of positive and negative expression of CD95 can be visualized when using this approach. The gate identifying CD95 + cells can then be copied in the same bivariate plot after gating for multiple naive markers, i.e., CD45RO, CCR7 and CD62L/CD27 for human cells and CD45RA, CCR7 and CD28 for rhesus macaques (Fig. 1a,b ). Negligible differences can be observed between experiments performed by different users and on different days by using the strategy we describe (Fig. 2b) .
Alternatively, the inclusion of more markers in the panel can improve separation of the T SCM cell population; for example, higher levels of CD58 and CD122 are found on T SCM cells compared with T N cells (Fig. 3a) . CD58-or CD122-specific antibodies are available conjugated to PE, and can be included in both panels 1 and 2 (Table1). For general advice on the development of more complex panels, refer to published guidelines 9 . Anti-CD95 clone DX2 antibody (like other CD95-specific antibodies) is capable of inducing apoptosis in target cells. Despite quiescent lymphocytes being generally resistant to CD95-induced apoptosis 10,11 , we suggest including sodium azide (NaN 3 ) in the staining buffer and keeping the sample cold during long FACS sorting procedures to minimize cellular metabolism.
When quantifying T SCM cells in human patient samples, peripheral blood lymphocytes from a healthy donor should ideally be included as a control to help set gates; we have found that T cells from patients with different pathologies or receiving different therapies may exhibit substantially altered representation of the subsets, making it difficult to judge delineation gates 'by eye' (E.L. and M.R., unpublished observation).
We use a similar combination of antibodies to track T SCM cells in rhesus macaques, based on the expression of CD45RA, CCR7, CD28 and CD95 (note that no anti-rhesus CD45RO reagents are currently available). In rhesus macaques, CD95 expression in the T SCM versus T N populations is not as distinct as in humans (Fig. 1b) , making isolation of T SCM cells for sorting more difficult. The addition of anti-CXCR3 to the panel can improve the identification of T SCM cells in CD8 + but not the CD4 + T cell lineage, as all NHP CD8 + but not CD4 + T SCM cells express CXCR3 (Fig. 1b) . Indeed, CXCR3 can replace CD95 for the identification and isolation of CD8 + T SCM cells in NHP (Fig. 1b) .
If flow cytometry sorting is planned, cell staining can be preceded by negative magnetic isolation of the target lineage (CD4 + or CD8 + ) to shorten the sorting time. Sorted cells can be subsequently expanded by stimulating them with a combination of IL-7, which preferentially expands T N , T SCM and T CM cells 4 , IL-15, which selectively expands memory cells 12 , or CD3/CD2/CD28-specific antibody-coated beads. In contrast to the latter, IL-7-and IL-15-mediated expansions partly maintain the initial phenotype of the population 4,13,14 rather than inducing excessive proliferation, acquisition of effector function and in vitro-induced senescence 15 .
To identify CD95 + cells, fluorescence minus one (FMO) controls (i.e., samples stained with all fluorochromes except the one of interest 1 ) are not fully informative in this particular example, as some T N cells can express low levels of CD95 (Fig. 1c) . These cells are not included in the T SCM cell gate because of the impossibility to clearly separate CD95 dull and CD95 -T N cells. Clear-cut separation of CD95 expression can be easily visualized by plotting CD95 versus CCR7, as described above. However, FMO controls can still be important to guide the gating procedure and to reveal compensation artifacts.
In this manuscript, flow cytometer setup is not discussed, as it has been thoroughly described in detail elsewhere 16 . In particular, the procedure described by Perfetto et al. 16 defines methods for setting detector photomultiplier (PMT) voltages in advance using quality control reagents, such as prestained beads, thereby ensuring the greatest signal-to-background separation. By using such procedures, no changes in PMT settings are needed before the initiation of the experiment, and thus the time spent at the machine is limited to the acquisition of the sample. Importantly, quality control of laser alignment, laser delays and PMT transmission should be checked before every experiment by running Rainbow beads, as described 16 . To minimize the time spent at the flow cytometer on the day of the experiment, we recommend that the experiment template be set up in advance. A rigorous quality control (QC) program for instrument alignment and settings is critical for reproducible evaluation of T SCM cells using polychromatic flow cytometry.
The MHC class I tetramer used here was synthesized and conjugated in our laboratory. The antibodies are commercially available from several companies, as listed in the Reagents section. All antibodies and tetramers should be carefully titrated before use, whether they are obtained commercially or synthesized in the laboratory. The titer giving the best separation over the background should be chosen. However, in some cases, a lower concentration of the antibody can be used to minimize 'spreading error' to other fluorochromes (i.e., after compensation) 17 . Detailed theoretical considerations and practical procedures regarding antibody-antigen binding for flow cytometric analyses have been discussed elsewhere 18 .
Applications of the protocol
The protocol described here has been optimized for the identification, isolation and in vitro expansion of human T SCM cells. NHP T SCM cells can be isolated with a similar panel. However, the same procedure, but with different monoclonal antibodies, can be used to identify and sort any T cell population from the human body for further studies and applications. Table 1 for specific antibodies required for particular staining conditions): anti-human CD3 MACS buffer Mix 5 ml of 0.5 M EDTA stock (5 mM) and 2.5 g of BSA, add PBS to adjust the volume to 500 ml, and then filter-sterilize and degas the solution. Prepare the buffer in advance and store it at 4 °C for up to 6 months. EB stock solution Mix 3 mg ml − 1 of EB in ethanol and store it in a dark bottle for 6 months at 4 °C. AO stock solution Mix 5 mg ml − 1 of AO in ethanol and store it in a dark bottle for 6 months at 4 °C. EB/AO working solution Add 10 µl of EB stock to 10 µl of AO stock and dilute it to 1 ml with PBS (final concentration of EB = 30 µg ml − 1 ; final concentration of AO = 50 µg ml − 1 ). Store the solution at 4 °C for up to 6 months. AQUA viability dye Thaw AQUA powder at 37 °C for 30 s, add 50 µl of DMSO, pipette thoroughly and store the mixture at − 20 °C for up to 3 months. Bead medium Mix 2% (vol/vol) FBS and 0.02% (wt/vol) NaN 3 in PBS. Store the medium at 4 °C for up to 1 month. R-NH2 AQUA CompBeads Make a 1:5 dilution of the bead stock with bead medium (~46.2 × 10 6 beads per ml); take 350 µl of this mixture (16 × 10 6 ), wash it in PBS and resuspend the beads in 300 µl of PBS. Add 100 µl of AQUA dye and incubate for 1.5 h. Wash the beads twice with bead medium and resuspend them in a 2-ml volume. Spike in an equal concentration (350 µl) of unstained amine beads. Add bead medium to obtain a final volume of 4 ml. Store the beads in a glass vial for up to 6 months at 4 °C. 
MaterIals
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2|
If flow cytometry sorting is planned, enrich CD4 + or CD8 + T-cell populations by negative selection according to the kit manufacturer's instructions.
3|
Add PBS to the cells to remove any residual proteins.
4|
Centrifuge the cell suspension for 5 min at 400g at room temperature (RT; 24 °C).
5|
Prepare AQUA working solution in excess (15% more than the volume needed for the experiment) by diluting the stock solution in water. Vortex the solution and add PBS to obtain the desired concentration as determined by titration. Vortex the solution again.  crItIcal step The amounts of AQUA and of antibody needed for the experiment are determined by titration experiments performed in advance. Use 100 µl of AQUA staining solution if up to 10 × 10 6 cells are stained. If more cells are used, consider that a 100 × 10 6 cell pellet corresponds to a volume of ~100 µl. If 100 µl of staining solution is used to stain such a number of cells, the final concentration of the dye (or of the antibody) will be diluted. Therefore, on the basis of our experience, we suggest preparing a staining solution containing 3× or 4× the concentration of the reagent to obtain a final volume of ~200 µl. The staining volume should be scaled up according to the number of cells. In any case, the optimal titer of antibodies to be used in sorting experiments can be determined by a titration experiment, where for instance 1×, 2×, 4× or 8× the amount of the antibody optimal for staining 10 6 cells is used. Detailed theoretical considerations and practical procedures regarding antibody binding to antigen for flow cytometric analyses can be found elsewhere 18 .
6|
Remove the supernatant from pelleted cells.
7|
Add AQUA working solution to the cell pellet, resuspend by pipetting and incubate the mixture for 15 min at RT in the dark. 9| Spin the mixture for 5 min at 400g at RT. In the meantime, prepare CCR7 staining solution in excess (15% more than the volume needed for the experiment as indicated in Step 5) in staining buffer 1. If NHP cells are to be stained, prepare CXCR3 staining solution at this step in the same buffer.  crItIcal step CCR7 and other chemokine receptors recycle through the plasma membrane. Do not include NaN 3 in the staining buffer, as it prevents the internalization of surface antigens and can produce a loss of fluorescence intensity. Refer to Step 5 for the amount of antibody needed to stain a large number of cells.
10|
Spin antibody staining solution in a microcentrifuge at 15,000g for 5 min at RT to remove antibody aggregates. Use the supernatant only to stain cells.
11|
After the cells have been pelleted (Step 10), discard the supernatant and add CCR7 staining solution, resuspend the cell pellet by pipetting and then incubate it for 20 min at 37 °C in the dark. If NHP cells are being used, perform CXCR3 staining at this stage.  crItIcal step Incubation at 37 °C allows CCR7 and CXCR3 to recycle through the plasma membrane and improves their detection by producing a gain of fluorescence. However, for rhesus macaques, we do not see any difference by staining for CCR7 at 37 °C versus RT.
12|
Add staining buffer II to wash the cells (use a volume that dilutes the staining solution by 20-30-fold) and spin the mixture for 5 min at 400g at RT. In the meantime, prepare surface staining antibody mix in excess (15% more than the volume needed for the experiment, as indicated in Step 5) . Centrifuge the antibody mix as indicated in Step 10.  crItIcal step Prepare this mix using staining buffer II containing NaN 3 to minimize cellular metabolism. Refer to
Step 5 for the amount of antibody needed to stain a large number of cells.
13| Remove the supernatant from pelleted cells.
14|
Add surface staining antibody mix to the cell pellet, resuspend it by pipetting and incubate the mixture for 20 min at RT in the dark. In the meantime, prepare compensation controls. Vortex CompBeads and aliquot 30 µl to each tube. Prepare a tube for each fluorochrome plus a tube with beads only (unstained negative control). For each type of CompBead used in the experiment, include the relative negative control.  crItIcal step CompBeads tend to form aggregates over time. Before use, sonicate CompBeads for 2 min.
15|
Add the fluorescently conjugated antibody to the tubes containing CompBeads at the same titer that is used for the staining; vortex the tubes and incubate them for 15 min at RT.
16|
Wash the sample and compensation controls by adding 2 ml of staining buffer II to each tube. Spin the sample for 5 min at 400g at RT. 
26|
If you are performing CFSE staining, proceed with the remainder of the procedure. First prepare the CFSE working solution by adding 2 µl of the stock to 1 ml of PBS (final concentration = 10 µM). Prewarm the solution to 37 °C before adding it to the cell pellet.
27| Discard the supernatant from the cell pellet.
28|
Add the appropriate volume of CFSE to achieve ~10 7 cells per ml. Vortex the mixture.
29|
Incubate the mixture for 7 min in a 37 °C water bath. 30| Add 1-2 ml of cold FBS to stop the reaction. Vortex and top up with R10.
31|
Centrifuge the tubes for 5 min at 400g at RT.
32|
Discard the supernatant and resuspend it in R10 at a density of 2.5 × 10 5 cells per ml.
33| Culture the cells in the presence of the appropriate stimuli. Leave some extra wells with unstimulated CFSE-stained cells to be used as a compensation control at the time of analysis. Unstained PBMCs will provide the appropriate negative control. If desired, collect the cells and stain for surface antigens as indicated in Steps 3-17.  crItIcal step Human T cell subsets can be efficiently expanded with CD3/CD2/CD28-specific beads, IL-7 or IL-15. NHP T cell subsets can be expanded by stimulating with plate-bound anti-CD3 and soluble anti-CD28 (final concentration = 1 µg ml − 1 ). Moreover, NHP CD8 + T cell subsets, with the exception of T N cells, can be expanded in the presence of human IL-15. CD3/CD2/CD28-specific beads should be used at a 1:2 bead-to-cell ratio to ensure optimal stimulation. IL-7 and IL-15 can both be used at a concentration of 25 ng ml − 1 . However, we recommend that antibody and cytokine concentrations be optimized according to the experimental need. 
antIcIpateD results
The panels indicated here allow the correct identification of human and NHP CD4 + and CD8 + T SCM cells (Fig. 1) . Naive-like cells, which include both true naive cells and T SCM cells, must be identified using at least three markers and are defined here as CD45RO -CCR7 + CD62L + in humans and as CD45RA + CCR7 + CD28 + in rhesus macaques (table 1) . In humans, if cryopreserved cells are being used, CD62L is replaced by a different marker (e.g., CD27, Fig. 1d and  table 1 ). Within naive-like cells, a subset expressing CD95, the T SCM population, can be identified (Fig. 1a,b) .
Adding an MHC class I tetramer allows the identification of antigen-specific T SCM cells by using the same gating strategy (Fig. 1d) .
The expected frequency of T SCM cells should be ~2-4% of the total CD4 + and CD8 + T-cell populations and does not change appreciably with the age of the donor (E.L., L.G., N.P.R. and M.R., unpublished observations). In our experience, the expected yield after sorting is one CD4 + T SCM cell per 250 PBMCs and one CD8 + T SCM cell per 500-1,000 PBMCs.
For human PBMCs, improved identification of the T SCM population can be achieved by including CD58 or CD122 in the staining panel, as these markers are differentially expressed in T SCM versus T N cells (Fig. 3a) . In rhesus macaques, adding CXCR3 ensures better separation of the CD8 + T SCM subset, as virtually all CD8 + T SCM cells are also CXCR3 + (Fig. 1b) .
Bulk T SCM cells, as well as other subsets, can be sorted by flow cytometry at high purity (Fig. 4) for subsequent genetic analysis, in vitro expansion and genetic manipulation. Indeed, stimulation with beads coated with CD3/CD2/CD28-specific antibodies or homeostatic cytokines induce cell cycle entry, thus allowing the transduction with retroviral vectors 21 . Genetically modified cells can then be used for adoptive transfer experiments.
Effective T SCM expansion in vitro is achieved by stimulating with beads coated with CD3/CD2/CD28-specific antibodies (human), plate-bound anti-CD3 and soluble anti-CD28 (NHP) or the homeostatic cytokines IL-7 and IL-15. In vitro, CD4 + T cells are preferentially expanded by IL-7, whereas CD8 + T cells respond to both IL-7 and IL-15 (ref. 22) . A differential response of human T N and memory cells is seen with these stimuli, as depicted in Figure 5 . Thus, we recommend that expansion conditions be optimized before proceeding with the experiment. A combination of both IL-7 and IL-15 can be used to maximize T cell stimulation 21 . Stimulation through CD3, CD2 and CD28 expands cells much more efficiently than the use of homeostatic cytokines, but it also causes a drastic change in the cell phenotype, including downregulation of CD45RA, CCR7 and CD62L with progressive proliferation as measured by CFSE dilution 4 . Thus, the user should choose the appropriate stimuli depending on the application. 
